News | November 13, 2024
Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
The company will address these observations within the stipulated timeline
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
New Board of Directors and management team at Suven Pharma also appointed
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)